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IMPORTANCE Extramammary Paget disease (EMPD) is a frequently recurring malignant

neoplasm with metastatic potential that presents in older adults on the genital, perianal, and
axillary skin. Extramammary Paget disease can precede or occur along with internal malignant
neoplasms.
OBJECTIVE To develop recommendations for the care of adults with EMPD.
EVIDENCE REVIEW A systematic review of the literature on EMPD from January 1990 to
September 18, 2019, was conducted using MEDLINE, Embase, Web of Science Core
Collection, and Cochrane Libraries. Analysis included 483 studies. A multidisciplinary expert
panel evaluation of the findings led to the development of clinical care recommendations for
EMPD.
FINDINGS The key findings were as follows: (1) Multiple skin biopsies, including those of any
nodular areas, are critical for diagnosis. (2) Malignant neoplasm screening appropriate for age
and anatomical site should be performed at baseline to distinguish between primary and
secondary EMPD. (3) Routine use of sentinel lymph node biopsy or lymph node dissection is
not recommended. (4) For intraepidermal EMPD, surgical and nonsurgical treatments may be
used depending on patient and tumor characteristics, although cure rates may be superior
with surgical approaches. For invasive EMPD, surgical resection with curative intent is
preferred. (5) Patients with unresectable intraepidermal EMPD or patients who are medically
unable to undergo surgery may receive nonsurgical treatments, including radiotherapy,
imiquimod, photodynamic therapy, carbon dioxide laser therapy, or other modalities.
(6) Distant metastatic disease may be treated with chemotherapy or individualized targeted
approaches. (7) Close follow-up to monitor for recurrence is recommended for at least the
first 5 years.
CONCLUSIONS AND RELEVANCE Clinical practice guidelines for EMPD provide guidance
regarding recommended diagnostic approaches, differentiation between invasive and
noninvasive disease, and use of surgical vs nonsurgical treatments. Prospective registries may
further improve our understanding of the natural history of the disease in primary vs
secondary EMPD, clarify features of high-risk tumors, and identify superior management
approaches.
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xtramammary Paget disease (EMPD) is an epithelial malignant neoplasm in apocrine gland–rich skin, including the
vulva, scrotum, and penis.1 Extramammary Paget disease
mimics inflammatory conditions, thereby delaying diagnosis. The cell
of origin is unknown, with apocrine origin presumed, but intraepidermal keratinocytes and Toker cells are also implicated.
Although most EMPD is confined to the epidermis (intraepidermal EMPD [epiEMPD]), it can also invade the dermis and penetrate
soft tissues (invasive EMPD [invEMPD]). Invasive EMPD can metastasize to regional lymph nodes (LNs) and other organs (metastatic
EMPD). This type is distinct from secondary EMPD, which may evolve
synchronously or asynchronously with an underlying adenocarcinoma. Mutational differences between secondary EMPD and associated underlying adenocarcinomas have been reported.2
The clinical practice guidelines presented are based on a systematic review of the literature. Recommendation statements
focus on diagnosis and workup of EMPD and management of primary EMPD, including metastatic disease.

Methods

Box. Principles of EMPD Management
Principles of EMPD Managementa
Overall Considerations

• The primary goal of the treatment of EMPD is complete excision
with clear surgical margins and preservation of function and
cosmesis. Refractory or localized intraepidermal disease may be
treated with clinical margin clearance or topical therapy. All
treatment decisions should be individualized based on clinical
presentation, medical history, and patient preference.
• No specific systemic therapy for advanced disease can be
recommended. Distant metastases are uncommon.
Screening

• Age-appropriate malignant neoplasm screening should be
performed at baseline to distinguish between primary and secondary EMPD (Grade A). Additional screening should be guided
by EMPD anatomical location, review of systems, physical examination, and laboratory tests or imaging findings. EMPD may precede an associated internal malignant neoplasm by 5 years.
• Routine use of sentinel LN biopsy in the workup of EMPD is not
recommended (Grade C).
Intraepidermal EMPD

A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
reporting guideline (eFigure, eMethods, and eTable 1 in the
Supplement). For guideline development, experts in EMPD from all
key stakeholder specialties were identified (by N.K., J.L.O., B.W., and
M.A.) through publication history, clinical expertise, and peer
nomination. Secondary review was performed (M.A.) to ensure that
all invitees had expertise in collaborative cancer research (eg,
participation in National Comprehensive Cancer Network guideline
groups or other oncology collaborative groups) and recognition as
thought leaders in EMPD or related malignant neoplasms. Key
questions included the following: “What are the best practices for
diagnosis and risk assessment of EMPD?” and “How is primary EMPD,
including metastatic disease, best managed?” Data extraction was
performed for 23 493 cases of EMPD from 483 reports from January
1990 to September 18, 2019, meeting inclusion criteria (by N.K., J.L.
O., B.W., J.X.W., V.H., and M.B.D.). A consensus meeting was held
by teleconference in May 2020. Draft recommendations were
iteratively reviewed until consensus was reached. Principles of EMPD
management are summarized in the Box.

Clinical Presentation and Workup for EMPD
Recommendation 1
Physical examination should include examination of pubic, inguinal, genital, perineal, perianal, and axillary regions and associated
regional LNs. Further examination may be tailored based on sex, presence of invasive disease, review of systems, and presence of discontinuous lesions (Grade C; category 2A).
The mean (SD) age of patients with EMPD was 70.7 (3.3) years
(9951 of 18 600 women [53.5%]; Table 1).3-6 The most common sites
of lesions were the vulva (44.8% [8325 of 18 600]) and penisscrotum (27.0% [5017 of 18 600]); 92.0% of lesions (17 112 of
18 600) were in regions normally covered by underwear. Men were
12.5-fold more likely to have perineal and perianal involvement.7 Only
E2
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• The decision regarding the extent of resection to obtain tumorfree margins should be individualized. If tumor-free margins are
desired, margin-controlled surgery (eg, MMS or CCPDMA) with
en face sectioning is preferred (Grade B).
• Primary nonsurgical therapy (eg, imiquimod and photodynamic
therapy) or other modalities (eg, carbon dioxide laser) may be
considered in cases in which the morbidity from surgery is high
(Grade D). Recurrences are common, and close surveillance is
recommended to monitor for recurrence and adverse effects.
Invasive EMPD

• Surgical resection with curative intent is recommended (Grade
B). Margin-controlled surgery (eg, MMS or CCPDMA) with en face
sectioning is preferred; however, preoperative mapping biopsies
combined with wide local excision can be considered as an alternative approach.
• Adjuvant nonsurgical therapies may be considered for noninvasive disease at the margins where continued surgical resection
may incur excess morbidity (Grade D).
• Radiotherapy with curative intent may be indicated in cases in
which surgery is not advised or feasible (Grade B). Radiotherapy
can be considered in the adjuvant setting after surgery for persistent or recurrent EMPD (Grade C).
Metastatic EMPD

• Metastatic EMPD may be treated with chemotherapy, targeted
therapy, or immune checkpoint inhibitors. Multidisciplinary tumor board consultation or clinical trial enrollment is recommended (Grade C).
Principles of Radiotherapy in EMPDa
Overall Considerations

• Consultation with a radiation oncologist familiar with EMPD is
recommended given the rare nature of the malignant neoplasm.
• When radiotherapy is selected, protracted fractionation is associated with improved function and cosmesis and should be considered, especially for poorly vascularized areas.
• Contraindications to radiotherapy include prior radiotherapy of
the target volume and genetic conditions that predispose patients to increased radiosensitivity (eg, ataxia telangiectasia).
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Table 1. Demographic Characteristics of Included Cases

Box. (continued)

Characteristic

Radiotherapy should be used with caution in patients with connective tissue diseases.

Cases reporting demographic data, total No. 18 600
Age, mean (SD), y

Primary Radiotherapy

Female

9951 (53.5)

Male

8649 (46.5)

Race and ethnicitya

Adjuvant Radiotherapy

• Tumor bed: data on dosing are limited. Reported dosing ranges
from 50 to 70 Gy with approximately 1.8 to 2.5 Gy per fraction.
Margins are respective of tumor location and potential for wide
subclinical spread (Grade C).
• Lymph node basin: data on dosing are limited. Reported dosing
ranges from 50 to 70 Gy with 1.8 to 2.5 Gy per fraction (Grade C).
• Recurrent tumor: dosing is poorly defined but may assist with
surgery for curative intent (Grade C).

American Indian or Alaska Native

0

Asian and Pacific Islander

6659 (35.8)

Black or African American

260 (1.4)

White

11 662 (62.7)

Location of EMPD
Vulvar

Abbreviations: CCPDMA, complete circumferential peripheral and deep
margin assessment; EMPD, extramammary Paget disease; LN, lymph node;
MMS, Mohs micrographic surgery.
All statements are consensus category 2A.

4.4% of patients (100 of 2298 within studies reporting) presented
with multiple lesions. The mean (SD) time from patient-reported
onset to diagnosis was 35.7 (13.8) months. The mean (SD) lesion diameter was 7.0 (2.7) cm. Most studies (62 of 92) reported recurrent lesions. Previous misdiagnoses included tinea cruris, candidiasis, eczema, fistula, and hemorrhoids.
Common clinical findings were erythema (35.8% [823 of 2298]),
erosion or ulceration (15.1% [347 of 2298]), hypopigmentation (11.2%
[258 of 2298]), nodules (10.1% [231 of 2298]), and “eczematous”
presentation (8.3% [191 of 2298]). Symptoms included pruritus
(28.1% [645 of 2298]; more common in the scrotum than the vulva)
and pain (5.4% [123 of 2298]; typically cutaneous but also dysuria).
Lymph node examination was reported in 896 cases, and 194
(21.7%) had lymphadenopathy (likely an overestimate given consensus opinion). Compared with positive results from sentinel LN
biopsy (SLNB), lymphadenopathy was associated with LN metastasis and worse overall survival. Sentinel LN biopsy is discussed further in recommendation 6.8

70.7 (3.3)

Sex

• In select cases for which surgical intervention is not possible or
preferred and for which topical treatments are not preferred,
primary radiotherapy may be used (Grade C).
• Data on dosing are limited. Reported dosing ranges from 30 to
70 Gy divided into at least 1.8 to 2.5 Gy per fraction. Mean recurrence rates are more than 30% (Grade C).

a

Cases, No. (% of total)
(N = 23 493)

8333 (44.8)

Penoscrotal

5022 (27.0)

“Genital”

1786 (9.6)

Perianal

1228 (6.6)

Inguinal

391 (2.1)

Perineal

372 (2.0)

Axillary

167 (0.9)

Otherb

1321 (7.1)

Cases within studies clearly reporting type,
total No.

13 509

EMPD type
Primary EMPD

11 064 (81.9)

Secondary EMPD

2441 (18.1)

Lesion diameter, mean (SD), cm
Case reporting clinical finds, total No.

7.0 (2.7)
2298

Clinical findings
Erythema

823 (35.8)

Erosion or ulceration

347 (15.1)

Hypopigmentation

258 (11.2)

Nodules

231 (10.1)

Eczematous

191 (8.3)

Abbreviation: EMPD, extramammary Paget disease.
a

Asian cases are likely underrepresented as some studies from Asia did not
specify ethnicity.

b

Other included pubic, abdominal, thigh, thoracic, gluteal, sacral, perioral,
scalp, and upper cutaneous lip. One study reported cases in patients with prior
immunosuppressive therapy3; this occurrence is possibly underreported.
Three studies reported a family history of cancer4-6; this occurrence is possibly
underreported.

Recommendation 2
A biopsy should be performed for refractory or atypical intertriginous, genital erythematous, or papulosquamous lesions. Multiple
biopsies may better characterize large, complex tumors, particularly nodular or thickened areas (Grade B; category 2A).
For large patches or plaques, multiple broad biopsies may be
required to collect sufficient skin samples for pathologic analysis.
Nodular or thickened areas may represent invasive disease,9,10 for
which biopsy to the level of adipose tissue is advised.
Histopathologically, EMPD cells are larger than keratinocytes,
have pale to finely granular cytoplasm, and are arranged as single
cells or cell clusters in the epidermis alone (epiEMPD) or in the dermis or deeper (invEMPD). One-third of reported cases were epiEMPD (32.1% [4255 of 13 259]), whereas the remainder were
jamaoncology.com

invEMPD. This finding likely represents publication bias given expert consensus that epiEMPD is more common. Twenty-six studies
noted depth of invasion: 10.2% (61 of 597) were microinvasive (defined as ⱕ1 mm dermal invasion), 70.2% (419 of 597) were frank dermal, and 19.6% (117 of 597) were subcutaneous or deeper. The mean
(SD) depth (reported in 5 studies [202 cases]) was 3.0 (1.0) mm.
Among invEMPD cases reporting depth, 59.2% (190 of 321) were
confined to the upper dermis, with the remainder in the reticular dermis. More than one-third of EMPD cases (39.0% [404 of 1036]) had
adnexal involvement. Hair follicle involvement and eccrine gland involvement were common, with a mean depth of 1.6 mm (range, 0.53.3 mm) among cases with hair follicle involvement and 2.4 mm
(range, 0.8-3.2 mm) among cases with eccrine gland involvement.11
(Reprinted) JAMA Oncology Published online January 20, 2022
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Invasive EMPD was associated with being 60 years of age or
older12 and recurrence.13 Invasive EMPD was associated with worse
outcomes, including nodal metastasis,12,14,15 distant metastasis,16 and
decreased overall survival.17 Lymphovascular invasion occurred in
18.1% (198 of 1094) of cases (20 studies). Perineural invasion was
rare. Lymphovascular invasion was associated with LN
metastasis.18,19

Recommendation 3
A diagnostic immunohistochemical panel for EMPD consisting of cytokeratin 7 (CK7)–positive, CK20-positive or CK20-negative, p63negative, SOX10-negative, and carcinoembryonic antigen (CEA)–
positive results is recommended. This panel can exclude histologic
mimics. CK20 and/or CDX2 positivity may potentially indicate secondary EMPD (Grade A; category 2A).
Histologic mimickers of EMPD include tumors exhibiting pagetoid spread, such as squamous cell carcinoma in situ (p63 positive), melanoma in situ (SOX10 positive), and, less commonly,
sebaceous carcinoma (p63 positive or negative and adipophilin positive) (eTable 2 in the Supplement). Site-specific markers include gross
cystic disease fluid protein (GCDFP15; genital EMPD with apocrine
involvement) and CDX2 and CK20 (perianal disease).20,21 Once diagnosis is confirmed, a suggested profile to screen for secondary
EMPD includes CK7-positive, CK20-positive, CDX2-positive,
GCDFP15-negative, and GATA3-negative results.22 Overexpression of ERBB2 (formerly HER2)12,13,23-25 and protein kinase B26-31 may
be associated with invasive disease and LN metastasis, but some
studies are conflicting.32

Recommendation 4
US Preventive Services Task Force age-appropriate and anatomical
location–directed baseline malignant neoplasm screening should be
performed to identify secondary EMPD. Laboratory tests and
imaging should be guided by EMPD anatomical location, review of
systems, physical examination, and laboratory test results or imaging
findings. Extramammary Paget disease may precede an associated
internal malignant neoplasm by 5 years (Grade A; category 2A).
Among primary EMPD cases including information on metastasis, 19.7% of patients (1859 of 9435) presented with nodal metastasis, 2.5% (240 of 9435) presented with distant metastasis,
0.07% (7 of 9435) presented with satellite metastasis, and 0.7% (69
of 9435) presented with unspecified information on metastasis.
Specified sites of distant metastasis included hepatic (61.3% [19 of
31]), skeletal (41.9% [13 of 31]), pulmonary (35.5% [11 of 31]), adrenal (16.1% [5 of 31]), thyroid (12.9% [4 of 31]), gallbladder (6.5% [2
of 31]), and peritoneal (6.5% [2 of 31]) metastasis. Metastasis after
presentation is discussed in recommendation 12.
Secondary EMPD was reported in 18.1% of patients (2441 of
13 509 with studies reporting the type of EMPD). In 12 cases, the underlying malignant neoplasm was not adenocarcinoma. Common adenocarcinomas were colorectal (215, including 59 anal and 47 rectal), breast (83), prostate (46), urothelial or bladder (44), gastric (18),
endometrial or ovarian (13), renal (5), and adnexal (39, including
sweat gland). Surveillance, Epidemiology, and End Results Program data demonstrated that secondary malignant neoplasms in
EMPD were elevated, with an excess absolute risk of 97.4 malignant neoplasms per 10 000 person-years.33,34 The interval between EMPD and internal malignant neoplasm diagnosis was speciE4
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fied in 438 cases. Eighty-nine cases (20.3%) arose within 1 year after
EMPD diagnosis. The remaining asynchronous cases occurred after a mean (SD) of 5.4 (2.0) years and, therefore, have an uncertain
association with EMPD.
Low true-positive rates and relatively high false-positive rates for
prostate-specific antigen (PSA) and CEA do not support screening by
laboratory testing for all EMPD cases. Although PSA is commonly reported (11 studies), the PSA level was elevated in 15.7% of patients (11
of 70) in 1 study, although none had prostate cancer.12 In another study,
4 of 15 occult malignant neoplasms in a 132-patient cohort were detected by PSA testing.35 The clinical implications of a lead-time diagnosis in the latter study are unknown. Carcinoembryonic antigen is
also commonly reported (10 studies), and the level was elevated in 1
study in 16.7% of patients (10 of 60), with 70.0% (7 of 10) having
metastases.36 Three additional studies reported similar findings.37-39
Pooled analysis suggests false-positive rates of 41%. One report
showed that initial CEA levels above 20 ng/mL (to convert to micrograms per liter, multiply by 1.0) indicated a worse disease course.39
Other blood tests, such as alpha-fetoprotein,40,41 cancer antigen
19-9,35 cell-free DNA,42 and CYFRA21-1 (cytokeratin 19 fragment),43,44
have been performed, with the last showing some promise in monitoring treatment response.44
Additional organ-specific studies included colonoscopy (20 studies), cystoscopy (18), sigmoidoscopy (6), endoscopy (6), mammography (6), Papanicolaou test (5), and bone scan (4). Given the prolonged lag time between EMPD diagnosis and identification of an
underlying malignant neoplasm, universal screening protocols are impractical and not cost-effective. Particularly when lesions are ill defined or invasive disease is identified, a review of systems and a consideration of the anatomical region of involvement should guide test
selection, such as anoscopy or colonoscopy for perianal EMPD, colposcopy and urine cytologic screening for vulvar EMPD, and urine cytologic screening and uroscopy for penile disease. Transvaginal ultrasonography and other imaging modalities may assist with ruling out
intra-abdominal malignant neoplasms. One group reported high detection rates of occult malignant neoplasms (11.4% [15 of 132]) within
the first year of diagnosis using PSA testing (prostate carcinoma, 4
cases), urine cytologic screening (urothelial carcinoma, 3 cases), and
mammography(breastcarcinoma,2cases).35 Althoughanothergroup
proposed more extensive patient testing with invEMPD, subgroup
analysis did not reveal a higher risk of secondary malignant neoplasms in patients with invEMPD compared with epiEMPD.45 Investigational diagnostic techniques include reflectance confocal
microscopy46-48 andopticalcoherencetomography.49 Thereisnovalidated staging system specific for EMPD.50

Recommendation 5
Advanced imaging (computed tomography, positron emission tomography/computed tomography, and magnetic resonance imaging)
may be used to screen for metastases if internal malignant neoplasms or lymphadenopathy are found on initial screening. It is particularly recommended to assess for regional lymphadenopathy
when palpable lymphadenopathy or histologically invasive disease
is present. The anatomical site may determine the preferred modality (Grade C; category 2A).
Computed tomography (44 studies, typically chest, abdomen,
and pelvis), ultrasonography (20 studies, typically abdominal and/or
pelvic), plain radiography (19 studies, typically chest radiograph),
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positron emission tomography/computed tomography (11 studies), and magnetic resonance imaging (9 studies) were used to identify metastasis or underlying malignant neoplasms. Internal malignant neoplasms were, in some cases, found incidentally on imaging
(18.8% [3 of 16]).38,51 Imaging may assist in identifying advanced contiguous malignant neoplasms (secondary EMPD extending from an
adjacent contiguous cutaneous adenocarcinoma), advanced disease after a positive focused malignant neoplasm screening workup,
histologically invasive disease, or lymphadenopathy. The rate of contiguous malignant neoplasms in 1 study was 23.0% (37 of 161),35
which was higher than in other reports.52

Recommendation 6
Broad, routine use of SLNB in EMPD is not recommended. There is
no evidence that a positive sentinel LN results in treatment that
changes disease-specific survival. Lymphadenopathy detected on
physical examination should be investigated by imaging and biopsy or fine needle aspirate (Grade C; category 2A).
Sentinel LN biopsy was used in 20 studies, particularly scrotal
EMPD studies.12 In 21.7% of cases (137 of 630), SLNB findings were
positive. Tumor invasion to the reticular dermis or subcutis were associated with positive SLNB (40.7% positivity rate [22 of 54] vs 0%
for epiEMPD).15,16 Tumor size and presence of nodules was not associated with positivity.53 Sentinel LN biopsy methods included isosulfan blue dye injection,18,54,55 radioisotope lymphoscintigraphy
with blue dye,15,18,55 and indocyanine green fluorescence.55,56 One
study compared indocyanine green fluorescence–navigated SLNB
with isosulfan blue dye injection and radioisotope lymphoscintigraphy, with the former proving more sensitive.55 In 1 study, there was
no difference in overall survival between SLNB-positive (16 of 107
cases [15.0%]) and SLNB-negative patients.18 The utility of identifying microscopic nodal disease is presently unknown. Because of
the relatively higher proportion of reported SLNB-positive cases, use
of SLNB in invasive EMPD and scrotal EMPD may be considered to
assist with prognosis and determining further workup. However, in
contrast to frank nodal disease detected by clinical examination or
imaging, it is unclear whether adjuvant therapy or LN dissection for
SLNB-positive cases improves disease-specific survival. A randomized clinical trial, a prospective database study, or a well-designed
cohort study would be useful in guiding future recommendations
for SNLB.

Management: epiEMPD and invEMPD
Management of EMPD varies based on patient factors, tumor characteristics, and medical specialty. A management algorithm is presented in Figure 1. Primary EMPD is commonly removed by surgery. Of the 10 178 cases treated surgically, 9225 (90.6%) were
treated with wide local excision (WLE), 400 (3.9%) with Mohs micrographic surgery (MMS), 506 (5.0%) with complete circumferential peripheral and deep margin assessment (CCPDMA), 34 (0.3%)
with WLE plus photodynamic therapy, and 13 (0.1%) with WLE plus
radiotherapy. The recurrence rate for WLE alone was 37.0% (507 of
1371); for margin-controlled surgery, 18.7% (120 of 642); and for
MMS, 11.2% (22 of 197) (Table 2).
The mean (SD) surgical margin was 1.9 (1.0) cm. With the use
of case-level data modeled for different anatomical sites, surgical
jamaoncology.com
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margins for 95% tumor clearance were 4 cm for penoscrotal or
vulvar sites and 3.5 cm for perianal and axillary sites. Techniques
for margin assessment included mapping biopsies,4,57-63 particularly at perianal and vulvar sites. Reported clinical utility is
mixed.9,57,58,64,65 Lymph node dissection was performed in 3.7%
of surgical cases (380 of 10 178), typically at the time of tumor
excision. The indication for LN dissection vs targeted removal of
clinically or radiologically identified affected LNs is unclear based
on the reported cases. There is no definitive evidence that LN dissection or resection of LN metastasis improves overall survival;
however, surgery within the LN basin may be considered based on
clinical judgment. Cases reported in the literature did not clarify
the indication for LN dissection.

Intraepidermal EMPD
Recommendation 7
Decisions regarding the extent of resection of epiEMPD for tumorfree margins should be individualized. Because progression-free survival is 1 to 3 years, various operative strategies may be considered
(Grade D; category 2A). If tumor-free margins are desired, margincontrolled surgery (eg, MMS or CCPDMA) with en face sectioning is
preferred (Grade B; category 2A). If complex reconstruction is performed, consider delaying reconstruction until negative margins are
confirmed and selecting reconstructive options that permit surveillance for recurrence (Grade D; category 2A).
The median (SD) progression-free survival for epiEMPD was 20.4
(12.8) months.66-69 Given the large size, chronicity, anatomical location, and patient-specific factors, excision of epidermal disease may
induce unnecessarily high morbidity. Patient-centered discussion of
treatment options, including observation, is important to guide management. If the decision is made to obtain complete tumor-free margins, margin-controlled techniques, such as MMS or CCPDMA, may
have lower recurrence rates. Multidisciplinary surgical care must be
considered when there is clinical perirectal and periurethral involvement. Immunohistochemistry (CK770,71 and CEA72) and periodic acidSchiff with diastase staining73 have been used with MMS to improve margin analysis. Recurrent epiEMPD can be retreated with
surgery, which appears not to increase mortality (based on clinical
experience of the guidelines group). For nonsurgical candidates, noninvasive therapies may be an option, albeit with likely higher recurrence rates (see recommendations 8 and 10).

Recommendation 8
Primary noninvasive therapy (eg, imiquimod and photodynamic
therapy) or other modalities (carbon dioxide laser therapy) may
be considered when morbidity from surgery is high. Adjuvant
nonsurgical therapies (eg, imiquimod) may be considered for epiEMPD at the margins when continued surgery may incur excess
morbidity (Grade D; category 2A). Surveillance is recommended
to monitor for recurrence and adverse effects (Grade C; category
2A).
Fifty-four studies described nonsurgical therapies. Primary treatment with imiquimod (276 cases) resulted in a 30% complete response rate, 35.4% recurrence rate (35 of 99), and a mean time of
8.8 months (range, 4.25-18.0 months) to recurrence. Common imiquimod regimens were 1 to 3 times per week for 0.75 to 4 months
(Reprinted) JAMA Oncology Published online January 20, 2022

© 2022 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 02/16/2022

E5

Clinical Review & Education Special Communication

Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease

Figure 1. Management Algorithm for Extramammary Paget Disease (EMPD)
Suspicious lesion

History and physical examination
Complete skin and regional lymph node examination
Biopsy
Multiple biopsies that include thickened or nodular areas
Consider scouting biopsies beyond clinical border

Indeterminate
Diagnostic panel
consisting of CK7+,
CK20 ±, p63–,
SOX10–, and CEA+

Consider rebiopsy

Extramammary Paget disease
Screening for internal malignant neoplasm markers CK20+, CDX2+, GCDFP–, and GATA3–a
Consider need for imaging (ultrasonography) or computed tomography
Evaluate any clinical lymphadenopathy
Risk factors for recurrence or poor prognosis
Advanced age; male sex; perianal, anorectal, or vaginal location; large subclinical extension;
presence of lymphovascular invasion; adnexal invasion; or high p53 expression
Secondary

Epidermal

MMS or
CCPDMA
(curative
intent)b

MMS or
CCPDMA
(clinical
clearance)b

Margin
control
unavailable

WLEc

Invasive

Ineligible
for surgery or
has several
comorbidities
RT

Nodal disease suspected

MMS or
Margin
CCPDMA
control
(curative unavailable
intent)b

Topical or
nonsurgical
modalities

WLEc

Ineligible
for surgery

Multidisciplinary
tumor board
referral

Multidisciplinary oncology referral

Metastasis

Surgery for primary tumor
Biopsy and excision of
involved lymph node

Consider RT of nodal basin

Multidisciplinary
tumor board referral

Clinical trials or targeted
therapy (eg, ERBB2+ - trastuzumab)

Consider adjuvant treatment
for recurrence preventiond

Follow-up algorithm

Expert opinion of the panel indicated that clearance of the immediate tumor
area rather than exhaustive clearance may be appropriate for very large
tumors, where subclinical spread is likely extensive and surgery is likely
morbid. If clinical clearance is chosen, close observation and adjuvant
treatment with topical immunotherapy should be considered. Radiotherapy
may also be considered when margin control is indeterminate or for positive
margins. Curative intent implies exhaustive tumor removal. Margin-control
and tissue-sparing techniques are recommended as first-line treatment.

Positive markers are indicated by a plus sign, while negative markers are
indicated by a minus sign. CCPDMA indicates complete circumferential
peripheral and deep margin assessment; CEA, carcinoembryonic antigen;
CK, cytokeratin; MMS, Mohs micrographic surgery; RT, radiotherapy; and
WLE, wide local excision.
a

b

Screening for internal synchronous malignant neoplasm is advised based on
the anatomical site involved. Screening paradigms are not standardized. Some
experts, however, suggest that patients with vulvar EMPD should receive
urine cytologic screening, colonoscopy, and pelvic ultrasonography, while
those with penoscrotal EMPD may undergo these investigations along with
additional screening for prostate cancer. In the absence of specific staging
criteria for EMPD, vulvar EMPD can be staged according to National
Comprehensive Cancer Network guidelines on vulvar carcinoma.

Wide local excision may be supplemented with scouting biopsies to identify
the degree of subclinical spread (respective of anatomical site).

d

Adjuvant therapy may be most helpful in settings where surgery is not
possible, margin control is not available, or clearance of the margins is not
desired or possible.

Intraepidermal EMPD has a small association with disease-specific survival.

(25 studies), with some more frequent and prolonged courses. For
photodynamic therapy (263 cases), typically using topical aminolevulinic acid or methyl aminolevulinate with 3 to 4 hours of incubation (with or without occlusion) with red light for 3 to 8 treatments spaced 1 to 4 weeks apart (21 studies), the recurrence rate
was 34.2% (13 of 38), with a median time to recurrence of 10 months
E6

c

(range, 3-30 months). Data for treatment with fluorouracil, carbon
dioxide laser, and combination topical therapies are limited. Limitations of primary topical therapy include poor compliance due to
skin irritation and possible residual or recurrent discontinuous tumor after treatment, which may complicate future treatment and
monitoring.
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Table 2. Outcomes With Margin-Controlled Surgery and Standard Excision for All Reported Cases
of Extramammary Paget Disease
Outcome

WLE alone

Margin controla

MMS

Recurrence rate, No./total No. (%)

507/1371 (37.0)

120/642 (18.7)

22/197 (11.2)

Recurrence-free interval, median (range), mo

24.3 (4.0-152.0)

33.5 (24.0-40.8)

32.5 (31.0-35.9)

Overall survival, No./total No. (%)

766/992 (77.2)

517/559 (92.5)

46/51 (90.2)

Follow-up, median (range), mo

41.0 (11.0-216.0)

36.0 (21.0-64.9)

43.5 (26.0-59.2)

Abbreviations: MMS, Mohs
micrographic surgery; WLE, wide
local excision.
a

Margin control refers to use of
either complete circumferential
peripheral and deep margin
assessment or MMS.

Invasive EMPD

Management: Metastatic Disease

Recommendation 9

Recommendation 11

Surgical resection with curative intent is recommended for
invEMPD. Margin-controlled surgery (eg, MMS or CCPDMA) with en
face sectioning is preferred; however, preoperative mapping biopsies combined with WLE can be considered as an alternative approach (Grade B; category 2A).
Primary topical or nonsurgical therapy is considered secondline treatment when curative surgery is not possible. Patients receiving palliative treatment may benefit from topical or nonsurgical therapies (Grade D; category 2A).
Invasive EMPD has higher rates of recurrence,74 metastasis,14,16
and death.36,75-77 Recurrence and mortality rates are lower with MMS
or CCPDMA than with WLE. Epidermal EMPD and invEMPD can present within the same lesion. Surgical clearance of at least the invasive portion is preferred. If removal of epiEMPD would lead to excess morbidity, adjuvant nonsurgical approaches may be used with
close follow-up.

Patients with metastatic EMPD may be considered for chemotherapy, targeted therapy, or immune checkpoint inhibitors. Multidisciplinary tumor board consultation or trial enrollment is recommended (Grade C; category 2A).
A total of 189 of 1270 cases (14.9%) were treated with chemotherapy. Combination regimens were not superior to sequential
single-agent cytotoxic therapy (commonly weekly docetaxel).86,87
Combination chemotherapy may be appropriate for patients with
good performance status, especially when a radiographic response is required.66 Use of single-agent docetaxel86 and lowdose fluorouracil with cisplatin has been reported in the treatment
of locally advanced EMPD, but data are limited to case series.88 Other
approaches include next-generation sequencing (PI3K [phosphatidylinositol 3-kinase] inhibitors), fluorescence in situ hybridization
(ERBB2 inhibitors), and molecular techniques to evaluate for mismatch repair or microsatellite instability or high mutational burden
(immune checkpoint inhibitors).2,29,89-93

Radiotherapy
Follow-up

Recommendation 10
Radiotherapy with curative intent may be indicated when surgery
is inadvisable or infeasible (Grade B; category 2A). Radiotherapy can
be considered in the adjuvant setting after surgery for persistent or
recurrent EMPD (Grade C; category 2A).
Radiation treatment fields should account for subclinical extension, especially when there is curative intent. Where possible,
treatment should extend 3.5 cm beyond the clinical border to encompass the tumor in 95% of cases. The decision to treat draining
nodal basins should be individualized. Field design should consider
injury to adjacent tissues.
Overall, 37 studies reported radiotherapy (commonly, electron beam, photons, and brachytherapy) in at least 1 case. Radiotherapy was the primary treatment modality in 7.5% of cases (263
of 3507) involving the primary tumor bed with or without the nodal
basin.36,78 Doses ranged from 30 to 64 Gy in 20 to 33 fractions. The
recurrence rate was 30.6% (11 of 36).17,79,80 Radiotherapy was used
for patients with recurrent cases81 and elderly patients with high potential surgical morbidity.82 In the adjuvant setting, radiotherapy was
used in 8.5% of cases (296 of 3466).83-85 Dosing ranged from 45
to 64.8 Gy (median dose, 50 Gy) and 59 to 70.2 Gy (median dose,
60 Gy) in 25 to 39 fractions (median fraction, 33) to the primary tumor and LN bed, respectively. The recurrence rate was 34.8% (16
of 46).83
jamaoncology.com

Recommendation 12
Physical examination, including LN examination, is recommended
every 3 to 6 months for 3 years and then every 6 to 12 months until
at least 5 years after diagnosis. Monitoring for internal malignant neoplasms or metastatic EMPD with imaging based on anatomical location may be considered for aggressive or invasive disease. To our
knowledge, there are no data to recommend the optimal frequency or type of imaging (Grade D; category 2A).
A clinical algorithm to guide follow-up is presented in Figure 2.
The mean (SD) follow-up was 53.5 (21.4) months. The mean (SD) recurrence rate after treatment was 27.5% (2.3%) (6189 of 22 505
cases). Local recurrence was most common (65.2% [542 of 831]),
followed by distant metastasis (23.7% [197 of 831]) and regional nodal
metastasis (11.1% [92 of 831]). Distant metastases were to the liver,
bone, lung, skin, brain, peritoneum or retroperitoneum, axilla, and
distant LN. The mean (SD) time to recurrence was 36.9 (24.0)
months. The mean (SD) overall survival of patients with EMPD was
107.5 (63.0) months. A shorter interval of less than 6 months between examinations is recommended for those with extensive or aggressive disease.
To our knowledge, no longitudinal studies have established surveillance of EMPD. Recommendations are based on the literature and
the approximately 20% probability of developing an internal
(Reprinted) JAMA Oncology Published online January 20, 2022
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Figure 2. Follow-up Algorithm for Extramammary Paget Disease
Follow-up
Clinical examination
History and physical examination every 3-6 mo for 3 y, then every 6-12 mo for 2 ya
Complete skin examination with a focus on the affected site
Regional lymph node examination
Treat any dermatosis at the site to assist in early detection of recurrence
Patient education
Self-examination and report of recurrence of symptoms
Importance of ongoing age-appropriate malignant neoplasm risk
Consider periodic ultrasonography of regional nodal basin for invEMPD or
high-risk patients

No recurrence

Recurrence

Continue to observe
as clinically indicated

Local

Nodal or distant
metastasis

MMS or CCPDMA

Multidisciplinary tumor
board referral (consider clinical
trial or targeted therapy)

CCPDMA indicates complete circumferential peripheral and deep margin
assessment; invEMPD, invasive extramammary Paget disease; and MMS, Mohs
micrographic surgery.
a

Recurrent tumors treated with surgery may be considered for adjuvant
radiotherapy.

malignant neoplasm within 5 years after diagnosis. Shorter intervals are suggested immediately after initial EMPD diagnosis.
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is most appropriate for physicians to exercise their clinical judgment to ensure follow-up examinations and monitoring by imaging
that best suits the clinical situation.

Conclusions
The diagnosis of EMPD is predicated on a high index of suspicion because misdiagnosis as inflammatory skin disease is common. Immunohistochemical stains may exclude histologic mimics. Management of EMPD, whether intraepidermal or invasive, focuses on
removal with clear histologic margins whenever possible. Tissueconserving, margin-controlled surgery techniques, such as MMS or
CCPDMA, are preferred when available. Nonsurgical treatments can
be considered for epiEMPD if surgical therapy is not appropriate. Sentinel LN biopsy, adjuvant radiotherapy, and LN dissection are not routinely recommended because of insufficient evidence and morbidity. Metastatic EMPD or secondary EMPD is best managed with
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needed to define the features of high-risk tumors and to further
clarify the management of this highly recurrent and potentially aggressive cancer.
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